SG11201503524PA - Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists - Google Patents

Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists

Info

Publication number: SG11201503524PA
Authority: SG; Singapore
Prior art keywords: gip; glp1; exendin; derivatives; trigonal
Prior art date: 2012-12-21

Application number

SG11201503524PA

Inventor

Torsten Haack

Michael Wagner

Bernd Henkel

Siegfried Stengelin

Andreas Evers

Martin Lorenz

Katrin Lorenz

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-21

Filing date

2013-12-19

Publication date

2015-06-29

2013-12-19 Application filed by Sanofi Sa filed Critical Sanofi Sa

2015-06-29 Publication of SG11201503524PA publication Critical patent/SG11201503524PA/en

Links

101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 2
102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 title 1
230000009977 dual effect Effects 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Obesity (AREA)
Immunology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)

SG11201503524PA 2012-12-21 2013-12-19 Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists SG11201503524PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12306647		2012-12-21
PCT/EP2013/077307 WO2014096145A1 (en)	2012-12-21	2013-12-19	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists

Publications (1)

Publication Number	Publication Date
SG11201503524PA true SG11201503524PA (en)	2015-06-29

Family

ID=47559233

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
SG11201503524PA SG11201503524PA (en)	2012-12-21	2013-12-19	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG11201503526UA SG11201503526UA (en)	2012-12-21	2013-12-19	Dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG10201705097PA SG10201705097PA (en)	2012-12-21	2013-12-19	Functionalized exendin-4 derivatives
SG11201504215PA SG11201504215PA (en)	2012-12-21	2013-12-19	Functionalized exendin-4 derivatives
SG11201503576XA SG11201503576XA (en)	2012-12-21	2013-12-19	Exendin-4 Derivatives

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
SG11201503526UA SG11201503526UA (en)	2012-12-21	2013-12-19	Dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG10201705097PA SG10201705097PA (en)	2012-12-21	2013-12-19	Functionalized exendin-4 derivatives
SG11201504215PA SG11201504215PA (en)	2012-12-21	2013-12-19	Functionalized exendin-4 derivatives
SG11201503576XA SG11201503576XA (en)	2012-12-21	2013-12-19	Exendin-4 Derivatives

Country Status (38)

Country	Link
US (5)	US9745360B2 (en)
EP (5)	EP3400957A1 (en)
JP (4)	JP2016506401A (en)
KR (4)	KR20150099548A (en)
CN (4)	CN104870009B (en)
AR (5)	AR099912A1 (en)
AU (4)	AU2013366692B2 (en)
BR (3)	BR112015014800A2 (en)
CA (4)	CA2895875A1 (en)
CL (2)	CL2015001751A1 (en)
CR (1)	CR20150358A (en)
CY (2)	CY1120030T1 (en)
DK (2)	DK2934567T3 (en)
DO (1)	DOP2015000156A (en)
EA (1)	EA031428B1 (en)
EC (1)	ECSP15031141A (en)
ES (2)	ES2688367T3 (en)
HK (4)	HK1211233A1 (en)
HR (2)	HRP20180092T1 (en)
HU (2)	HUE035803T2 (en)
IL (4)	IL238623A0 (en)
LT (2)	LT2934568T (en)
MA (1)	MA38276B1 (en)
MX (4)	MX362190B (en)
PE (1)	PE20151239A1 (en)
PH (1)	PH12015501291B1 (en)
PL (2)	PL2934568T3 (en)
PT (2)	PT2934568T (en)
RS (1)	RS57531B1 (en)
RU (3)	RU2015129788A (en)
SG (5)	SG11201503524PA (en)
SI (2)	SI2934568T1 (en)
TN (1)	TN2015000283A1 (en)
TW (4)	TW201441252A (en)
UA (1)	UA116553C2 (en)
UY (4)	UY35233A (en)
WO (4)	WO2014096149A1 (en)
ZA (1)	ZA201503914B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
UA111305C2 (en)	2012-12-21	2016-04-11	Пфайзер Інк.	Condensed with lactams of aryl and heteroaryl
EP3421482A1 (en)	2012-12-21	2019-01-02	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
SG11201503524PA (en) *	2012-12-21	2015-06-29	Sanofi Sa	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG11201507934PA (en)	2013-05-28	2015-10-29	Takeda Pharmaceutical	Peptide compound
KR102310389B1 (en)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	Gip-glp-1 dual agonist compounds and methods
US10131702B2 (en) *	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
TW201609795A (en)	2013-12-13	2016-03-16	賽諾菲公司	EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609799A (en)	2013-12-13	2016-03-16	賽諾菲公司	Dual GLP-1/GIP receptor agonists
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
LT3157915T (en)	2014-06-17	2019-04-25	Pfizer Inc.	Substituted dihydroisoquinolinone compounds
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
JP6898231B6 (en)	2014-10-29	2021-07-28	ジーランドファーマアクティーゼルスカブ	GIP agonist compounds and methods
EA035527B1 (en)	2014-12-30	2020-06-30	Ханми Фарм. Ко., Лтд.	Glucagon derivatives with improved stability
JOP20200119A1 (en)	2015-01-09	2017-06-16	Lilly Co Eli	Gip and glp-1 co-agonist compounds
KR101661332B1 (en) *	2015-05-28	2016-09-29	(의료)길의료재단	Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 receptor agonist
US10993993B2 (en)	2015-05-28	2021-05-04	Immunoforge Co., Ltd.	Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en) *	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2017003191A1 (en)	2015-06-30	2017-01-05	Hanmi Pharm. Co., Ltd.	Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (en)	2015-07-10	2017-02-16	賽諾菲公司	New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
TWI622596B (en)	2015-10-26	2018-05-01	美國禮來大藥廠	Glucagon receptor agonists
KR102741433B1 (en)	2015-12-14	2024-12-10	안타로스 메디컬 에이비	Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
KR102508651B1 (en)	2015-12-23	2023-03-13	더 존스 홉킨스 유니버시티	Long-acting GLF-1R agonists as therapy of the nervous system and neurodegenerative conditions
CN113546159B (en) *	2015-12-29	2023-09-08	派格生物医药(苏州)股份有限公司	Compositions comprising GLP-1 receptor agonists and glucagon receptor agonists and uses thereof
CN115920077A (en)	2015-12-31	2023-04-07	韩美药品株式会社	Long-acting conjugates of glucagon/GLP-1/GIP receptor triple agonists
WO2017153575A1 (en) *	2016-03-10	2017-09-14	Medimmune Limited	Glucagon and glp-1 co-agonists for the treatment of obesity
EP3467106A4 (en) *	2016-05-24	2020-02-26	Takeda Pharmaceutical Company Limited	PEPTIDE COMPOUND
CN109641035A (en)	2016-06-29	2019-04-16	韩美药品株式会社	Glucagon derivative, includes its composition and its therapeutical uses at its conjugate
TW201821434A (en)	2016-10-10	2018-06-16	法商賽諾菲公司	Method of preparing peptides comprising a lipophilically modified lysine side chain
US10774127B2 (en) *	2016-10-12	2020-09-15	University Of Copenhagen	Peptide dual agonists of GIPR and GLP2R
AR110300A1 (en) *	2016-12-02	2019-03-13	Sanofi Sa	COMPOUNDS AS TRIGONAL PEPTIDE AGONISTS OF GLP1 / GLUCAGÓN / GIP RECEPTORS
AR110299A1 (en)	2016-12-02	2019-03-13	Sanofi Sa	CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid
AR110301A1 (en)	2016-12-02	2019-03-13	Sanofi Sa	COMPOUNDS AS GLP1 / GLUCAGÓN / GIP RECEPTING AGENISTS
US10392366B2 (en)	2017-02-21	2019-08-27	Sanofi	Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
JOP20180028A1 (en)	2017-03-31	2019-01-30	Takeda Pharmaceuticals Co	Polypeptide compound
AR112760A1 (en) *	2017-07-19	2019-12-11	Novo Nordisk As	BIFUNCTIONAL COMPOUNDS INCLUDING A GLP-1 ANALOGUE AND AN EGF ANALOGUE (A)
EP3664833B1 (en)	2017-08-09	2023-05-31	Sanofi	Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
CN109836488B (en) *	2017-11-24	2022-08-23	浙江道尔生物科技有限公司	Glucagon analogues for treating metabolic diseases
GB201720187D0 (en)	2017-12-04	2018-01-17	Imperial Innovations Ltd	Novel Compounds
DK3774862T3 (en)	2018-04-05	2022-09-05	Sun Pharmaceutical Ind Ltd	New GLP-1 analogs
BR112020020652A2 (en)	2018-04-10	2021-03-02	Sanofi-Aventis Deutschland Gmbh	method for cleaving peptides bound to the solid phase from the solid phase
EP3774838B1 (en)	2018-04-10	2022-08-10	Sanofi-Aventis Deutschland GmbH	Lixisenatide synthesis with capping
TWI829687B (en)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
UY38249A (en)	2018-05-30	2019-12-31	Sanofi Sa	CONJUGATED PRODUCTS INCLUDING A TRIPLE GLP-1 / GLUCAGON / GIP RECEPTOR AGONIST, A CONNECTOR AND HYALURONIC ACID
TWI749381B (en) *	2018-11-01	2021-12-11	美商美國禮來大藥廠	Protein tyrosine-tyrosine analogs and methods of using the same
KR102119188B1 (en) *	2018-11-13	2020-06-08	이뮤노포지 주식회사	Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor
CN113453703A (en) *	2018-12-21	2021-09-28	韩美药品株式会社	Pharmaceutical compositions comprising insulin and triple agonists active at both glucagon and GLP-1 and GIP receptors
JP2022516439A (en)	2018-12-21	2022-02-28	ジエンスヘンルイメデイシンカンパニーリミテッド	Bispecific protein
WO2020143625A1 (en) *	2019-01-07	2020-07-16	鸿绪生物医药科技（北京）有限公司	Novel polypeptide and therapeutic uses thereof
AU2020256648A1 (en) *	2019-04-11	2021-11-04	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Multi-receptor agonist and medical use thereof
WO2020214013A1 (en) *	2019-04-19	2020-10-22	한미약품 주식회사	Therapeutic use, for hyperlipideamia, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
WO2020214012A1 (en) *	2019-04-19	2020-10-22	한미약품 주식회사	Preventive or therapeutic pharmaceutical composition for hyperlipidemia comprising triple agonist acting on all of glucagon, glp-1 and gip receptors, or conjugate thereof, and preventive or therapeutic method
GB201908424D0 (en) *	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
MX2022001975A (en)	2019-08-16	2022-03-11	Applied Molecular Transport Inc	Compositions, formulations, and interleukin production and purification.
CN111040022B (en) *	2019-12-23	2021-12-14	万新医药科技(苏州)有限公司	Triplex agonists directed to glucagon-like peptide-1 receptor, glucagon receptor, and pepstatin receptor
AR121093A1 (en) *	2020-01-23	2022-04-20	Lilly Co Eli	GIP / GLP1 COAGONIST COMPOUNDS
AU2021229621B2 (en)	2020-03-06	2023-08-31	Sanofi	Peptides as selective GIP receptor agonists
CN115348876A (en)	2020-03-31	2022-11-15	安塔罗斯医疗公司	Selective GIP receptor agonists comprising chelating moieties for imaging and therapeutic purposes
KR20210129614A (en) *	2020-04-20	2021-10-28	한미약품 주식회사	Composition for prevention or treatment of hyperlipidemia comprising Trigonal glucagon/GLP-1/GIP receptor agonist or a conjugate thereof and method using the same
TW202144393A (en) *	2020-05-29	2021-12-01	大陸商北京拓界生物醫藥科技有限公司	A dual-agonist compound for both glp-1r and gipr and the use thereof
WO2022007805A1 (en) *	2020-07-06	2022-01-13	鸿绪生物医药科技（北京）有限公司	Novel polypeptide and therapeutic use thereof
CN116133677A (en) *	2020-07-06	2023-05-16	鸿绪生物医药科技（北京）有限公司	Novel polypeptide formulations and therapeutic uses thereof
WO2022018186A1 (en)	2020-07-22	2022-01-27	Novo Nordisk A/S	Co-agonists at glp-1 and gip receptors suitable for oral delivery
TW202214679A (en)	2020-07-22	2022-04-16	丹麥商諾佛儂迪克股份有限公司	Glp-1 and gip receptor co-agonists
JP2023538871A (en) *	2020-08-12	2023-09-12	ティーエックスピーファーマエージー	Exendin-4 peptide analog
US20230391845A1 (en)	2020-10-30	2023-12-07	Novo Nordisk A/S	Glp-1, gip and glucagon receptor triple agonists
CN114617956B (en) *	2020-12-10	2023-10-03	江苏中新医药有限公司	High-efficiency hypoglycemic protein medicine
CN117222661A (en) *	2021-03-25	2023-12-12	博瑞生物医药（苏州）股份有限公司	Dual receptor agonists of GIP and GLP-1, pharmaceutical compositions and uses
US12215133B2 (en)	2021-03-25	2025-02-04	Brightgene Bio-Medical Technology Co., Ltd.	GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
EP4353249A1 (en)	2021-05-26	2024-04-17	The United Bio-Technology (Hengqin) Co., Ltd.	Multi-agonist and use thereof
TW202317606A (en) *	2021-06-18	2023-05-01	大陸商北京拓界生物醫藥科技有限公司	Glucagon analogs and the pharmaceutical use thereof
CN115572326B (en) *	2021-06-21	2025-01-10	广东东阳光药业股份有限公司	Triple agonist of GLP-1, GCG and GIP receptors
TW202313667A (en) *	2021-07-30	2023-04-01	大陸商南京明德新藥研發有限公司	Polypeptide compound containing lactamide bridge
AU2022339059A1 (en)	2021-09-06	2024-05-02	Sanofi	New peptides as potent and selective gip receptor agonists
WO2023098777A1 (en) *	2021-12-01	2023-06-08	江苏恒瑞医药股份有限公司	Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
TW202330584A (en)	2022-01-20	2023-08-01	丹麥商諾佛儂迪克股份有限公司	Prodrugs and uses thereof
CN117603364A (en) *	2022-09-30	2024-02-27	广西医科大学附属肿瘤医院	A class of GLP-1/glucagon/Y2 receptor triple agonists and their applications
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
GB202302686D0 (en) *	2023-02-24	2023-04-12	Imperial College Innovations Ltd	Novel compounds
WO2025016303A1 (en) *	2023-07-14	2025-01-23	北京拓界生物医药科技有限公司	Glp-1, gip and gcg receptor triagonist and use thereof
CN118440155B (en) *	2024-07-11	2024-11-22	中国药科大学	A dual agonist polypeptide compound and its medical use

Family Cites Families (437)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5641757A (en)	1994-12-21	1997-06-24	Ortho Pharmaceutical Corporation	Stable 2-chloro-2'-deoxyadenosine formulations
US6858576B1 (en)	1996-08-08	2005-02-22	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
CZ300837B6 (en)	1996-08-30	2009-08-26	Novo Nordisk A/S	GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
JP4798814B2 (en)	1997-01-07	2011-10-19	アミリン・ファーマシューティカルズ，インコーポレイテッド	Use of exendin and its agonists to reduce food intake
US7312196B2 (en)	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6410511B2 (en)	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6723530B1 (en)	1997-02-05	2004-04-20	Amylin Pharmaceuticals, Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
AU749914B2 (en)	1997-08-08	2002-07-04	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
US7220721B1 (en)	1997-11-14	2007-05-22	Amylin Pharmaceuticals, Inc.	Exendin agonist peptides
AU757748B2 (en)	1997-11-14	2003-03-06	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
DE69839021T3 (en)	1997-11-14	2013-08-08	Amylin Pharmaceuticals, Llc	NOVEL EXENDIN AGONISTS
ATE410182T1 (en)	1998-01-09	2008-10-15	Amylin Pharmaceuticals Inc	FORMULATIONS FOR AMYLIN PEPTID AGONISTS WITH INSULIN
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
EP1056775B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU2612599A (en)	1998-03-13	1999-10-11	Novo Nordisk A/S	Stabilized aqueous peptide solutions
US6998387B1 (en)	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
CZ294848B6 (en)	1998-06-12	2005-03-16	Amylin Pharmaceuticals, Inc.	Glucagon-like peptide-1 improving beta -cell response to glucose in subjects with impaired glucose tolerance
WO2000009666A2 (en)	1998-08-10	2000-02-24	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
CA2343268A1 (en)	1998-09-17	2000-03-23	Eli Lilly And Company	Protein formulations
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
ES2249933T3 (en)	1998-12-22	2006-04-01	Eli Lilly And Company	SELF-STABLE FORMULATION OF PEPTIDE 1 GLUCAGON TYPE.
DK1143989T3 (en)	1999-01-14	2007-04-16	Amylin Pharmaceuticals Inc	Exendins for glucagon suppression
CN100356978C (en)	1999-01-14	2007-12-26	安米林药品公司	Novel exendin agonist formulations and methods administration thereof
US20030087820A1 (en)	1999-01-14	2003-05-08	Young Andrew A.	Novel exendin agonist formulations and methods of administration thereof
US7399489B2 (en)	1999-01-14	2008-07-15	Amylin Pharmaceuticals, Inc.	Exendin analog formulations
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
EP1956000B1 (en)	1999-03-17	2016-10-05	Novo Nordisk A/S	Acylating agents useful for acylating peptides
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
CA2372214A1 (en)	1999-04-30	2000-11-09	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6849714B1 (en)	1999-05-17	2005-02-01	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DK1180121T3 (en)	1999-05-17	2004-03-01	Conjuchem Inc	Long-acting insulinotropic peptides
US6887470B1 (en)	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6482799B1 (en)	1999-05-25	2002-11-19	The Regents Of The University Of California	Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6972319B1 (en)	1999-09-28	2005-12-06	Bayer Pharmaceuticals Corporation	Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
CA2396157A1 (en)	2000-01-10	2001-07-19	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
WO2001068112A2 (en)	2000-03-14	2001-09-20	Goeke Burkhard	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
CA2380423A1 (en)	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
US6706689B2 (en)	2000-05-19	2004-03-16	Amylin Pharmaceuticals, Inc.	Treatment of acute coronary syndrome with GLP-1
EP1317412A1 (en)	2000-08-18	2003-06-11	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US7507714B2 (en)	2000-09-27	2009-03-24	Bayer Corporation	Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
EP1330261B1 (en)	2000-10-20	2010-06-09	Amylin Pharmaceuticals, Inc.	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
ATE437891T1 (en)	2000-12-07	2009-08-15	Lilly Co Eli	GLP-1 FUSION PROTEINS
CN1501809B (en)	2000-12-13	2012-10-10	伊莱利利公司	Chronic treatment regimen using glucagon-like insulinotropic peptides
GB2371227A (en)	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
CN1162446C (en)	2001-05-10	2004-08-18	上海华谊生物技术有限公司	Insulinotropic hormone secretion peptide derivative
WO2002098348A2 (en)	2001-06-01	2002-12-12	Eli Lilly And Company	Glp-1 formulations with protracted time action
DK1412384T3 (en)	2001-06-28	2008-04-28	Novo Nordisk As	Stable formulation of modified GLP-1
CA2652991A1 (en)	2001-07-16	2003-11-13	Caprotec Bioanalytics Gmbh	Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
ATE536881T1 (en)	2001-07-31	2011-12-15	Us Gov Health & Human Serv	GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF
CN1635900A (en)	2001-08-28	2005-07-06	伊莱利利公司	Pre-mixes of GLP-1 and basal insulin
CN1571676A (en)	2001-10-19	2005-01-26	伊莱利利公司	Biphasic mixtures of GLP-1 and insulin
EP1463752A4 (en)	2001-12-21	2005-07-13	Human Genome Sciences Inc	Albumin fusion proteins
EP2277910A1 (en)	2001-12-21	2011-01-26	Human Genome Sciences, Inc.	Albumin fusion proteins
US7105489B2 (en)	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
US20050148497A1 (en)	2002-02-20	2005-07-07	Khan Mohammed A.	Method for administering glp-1 molecules
PL215168B1 (en)	2002-02-27	2013-10-31	Immunex Corp	Polypeptide formulation
EP1502102B1 (en)	2002-03-11	2009-01-14	caprotec bioanalytics GmbH	Compounds and methods for analyzing the proteome
US7141240B2 (en)	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
AU2003226913A1 (en)	2002-04-04	2003-10-20	Novo Nordisk A/S	Glp-1 agonist and cardiovascular complications
CA2480858A1 (en)	2002-04-10	2003-10-23	Eli Lilly And Company	Treatment of gastroparesis
US6861236B2 (en)	2002-05-24	2005-03-01	Applied Nanosystems B.V.	Export and modification of (poly)peptides in the lantibiotic way
US20040037826A1 (en)	2002-06-14	2004-02-26	Michelsen Birgitte Koch	Combined use of a modulator of CD3 and a GLP-1 compound
WO2003105897A1 (en)	2002-06-14	2003-12-24	Novo Nordisk A/S	Combined use of a modulator of cd3 and a glp-1 compound
DE10227232A1 (en)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Sour insulin preparations with improved stability
JP5685355B2 (en)	2002-07-04	2015-03-18	ジーランドファーマアクティーゼルスカブ	GLP-1 and method for treating diabetes
WO2004004780A1 (en)	2002-07-09	2004-01-15	Sandoz Ag	Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20070065469A1 (en)	2002-07-09	2007-03-22	Michael Betz	Liquid formulations with high concentration of human growth hormone (high) comprising glycine
EP2409686A1 (en)	2002-08-01	2012-01-25	Mannkind Corporation	Cell transport compositions and uses thereof
US20040038865A1 (en)	2002-08-01	2004-02-26	Mannkind Corporation	Cell transport compositions and uses thereof
US20080260838A1 (en)	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
CN102964347B (en)	2002-08-21	2015-11-18	勃林格殷格翰制药两合公司	8-[3-amino-piperadine-1-base]-Xanthine compounds, its preparation method and the purposes as pharmaceutical preparation
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP2006517908A (en)	2002-10-02	2006-08-03	ジーランド・ファーマ・ア／エス	Stabilized exendin-4 compound
US6969702B2 (en)	2002-11-20	2005-11-29	Neuronova Ab	Compounds and methods for increasing neurogenesis
DE60335743D1 (en)	2002-11-20	2011-02-24	Neuronova Ab	COMPOUNDS AND METHOD FOR INCREASING THE NEUROGENESIS
US20050209142A1 (en)	2002-11-20	2005-09-22	Goran Bertilsson	Compounds and methods for increasing neurogenesis
JP2006514035A (en)	2002-12-17	2006-04-27	アミリン・ファーマシューティカルズ，インコーポレイテッド	Prevention and treatment of cardiac arrhythmias
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en)	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
CA2521784C (en)	2003-04-08	2012-03-27	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
WO2004089985A1 (en)	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
WO2004103390A2 (en)	2003-05-15	2004-12-02	Trustees Of Tufts College	Stable analogs of peptide and polypeptide therapeutics
US7947261B2 (en)	2003-05-23	2011-05-24	Nektar Therapeutics	Conjugates formed from polymer derivatives having particular atom arrangements
AU2004251602B2 (en)	2003-05-23	2010-05-13	Nektar Therapeutics	PEG derivatives having an amidocarbonate linkage
ES2425221T3 (en)	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	New methods and compositions for enhanced transmucosal delivery of peptides and proteins
JP4936884B2 (en)	2003-06-03	2012-05-23	ノボ・ノルデイスク・エー／エス	Stabilized pharmaceutical peptide composition
CN1812808B (en)	2003-06-03	2012-07-04	诺沃挪第克公司	Stabilized pharmaceutical peptide compositions
PL1633391T3 (en)	2003-06-03	2012-03-30	Novo Nordisk As	Stabilized pharmaceutical peptide compositions
AU2004243531B2 (en)	2003-06-03	2009-11-05	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
US8921311B2 (en)	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
JP4463814B2 (en)	2003-08-05	2010-05-19	ノボノルディスクアクティーゼルスカブ	New insulin derivatives
AU2004266757A1 (en)	2003-08-21	2005-03-03	Novo Nordisk A/S	Separation of polypeptides comprising a racemized amino acid
US20060247167A1 (en)	2003-09-01	2006-11-02	Novo Nordisk A/S	Stable formulations of peptides
JP5518282B2 (en)	2003-09-01	2014-06-11	ノヴォノルディスクアー／エス	Stable peptide formulation
EP1667724A2 (en)	2003-09-19	2006-06-14	Novo Nordisk A/S	Albumin-binding derivatives of therapeutic peptides
WO2005046716A1 (en)	2003-11-13	2005-05-26	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
US20050281879A1 (en)	2003-11-14	2005-12-22	Guohua Chen	Excipients in drug delivery vehicles
US20050106214A1 (en)	2003-11-14	2005-05-19	Guohua Chen	Excipients in drug delivery vehicles
EP1750752A2 (en)	2003-11-20	2007-02-14	Neuronova AB	Compounds and methods for increasing neurogenesis
HUE038395T2 (en)	2003-11-20	2018-10-29	Novo Nordisk As	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
JP5697831B2 (en)	2003-12-03	2015-04-08	ノヴォノルディスクアー／エス	Single chain insulin
EP1691841B1 (en)	2003-12-10	2020-09-09	Nektar Therapeutics	Compositions comprising two different populations of polymer-active agent conjugates
US20050143303A1 (en)	2003-12-26	2005-06-30	Nastech Pharmaceutical Company Inc.	Intranasal administration of glucose-regulating peptides
US20060210614A1 (en)	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide
CN1938334A (en) *	2004-01-30	2007-03-28	瓦拉塔药品公司	Combined use of a GLP-1 agonist and gastrin compounds
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
NZ571824A (en)	2004-02-11	2010-04-30	Amylin Pharmaceuticals Inc	Amylin family peptides and methods for making and using them
NZ579621A (en)	2004-02-11	2011-03-31	Amylin Pharmaceuticals Inc	Hybrid polypeptides with selectable properties
EP2335716A3 (en)	2004-02-11	2011-10-19	Amylin Pharmaceuticals Inc.	Pancreatic polypeptide family motifs and polypeptides comprising the same
US7399744B2 (en)	2004-03-04	2008-07-15	Amylin Pharmaceuticals, Inc.	Methods for affecting body composition
SI2409707T1 (en)	2004-04-15	2015-07-31	Alkermes Pharma Ireland Limited	Polymer-based sustained release device
US7456254B2 (en)	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
US20060110423A1 (en)	2004-04-15	2006-05-25	Wright Steven G	Polymer-based sustained release device
WO2005117584A2 (en)	2004-05-28	2005-12-15	Amylin Pharmaceuticals, Inc	Improved transmucosal delivery of peptides and proteins
US20090069226A1 (en)	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
WO2005120492A1 (en)	2004-06-11	2005-12-22	Novo Nordisk A/S	Counteracting drug-induced obesity using glp-1 agonists
PL2626368T3 (en)	2004-07-19	2017-06-30	Biocon Limited	Insulin-oligomer conjugates, formulations and uses thereof
KR20070039593A (en)	2004-07-21	2007-04-12	암브룩스, 인코포레이티드	Biosynthetic polypeptides using non-naturally encoded amino acids
MX2007001424A (en)	2004-08-03	2008-03-13	Biorexis Pharmaceutical Corp	Combination therapy using transferrin fusion proteins comprising glp-1.
US20070204633A1 (en)	2004-08-16	2007-09-06	Whisson Maxwell E	Apparatus and Method for Cooling of Air
ES2442223T3 (en)	2004-08-31	2014-02-10	Novo Nordisk A/S	Use of tris (hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
DE102004043153B4 (en)	2004-09-03	2013-11-21	Philipps-Universität Marburg	Invention relating to GLP-1 and exendin
JP5060131B2 (en)	2004-09-07	2012-10-31	中外製薬株式会社	Method for producing water-soluble hyaluronic acid modified product
US20080280814A1 (en)	2004-09-17	2008-11-13	Novo Nordisk A/S	Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
MX344532B (en)	2004-10-01	2016-12-19	Ramscor Inc	Conveniently implantable sustained release drug compositions.
WO2006037811A2 (en)	2004-10-07	2006-04-13	Novo Nordisk A/S	Protracted exendin-4 compounds
US7595294B2 (en)	2004-10-08	2009-09-29	Transition Therapeutics, Inc.	Vasoactive intestinal polypeptide pharmaceuticals
US20090036355A1 (en)	2004-10-13	2009-02-05	Sanjay Bhanot	Antisense Modulation of PTP1B Expression
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
CN112618700A (en)	2004-11-12	2021-04-09	诺和诺德公司	Stable formulations of insulinotropic peptides
PL1817048T3 (en)	2004-11-12	2014-07-31	Novo Nordisk As	Stable formulations of insulinoptropic peptides
US20090011976A1 (en)	2004-11-12	2009-01-08	Novo Nordisk A/S	Stable Formulations Of Peptides
SG157423A1 (en)	2004-12-02	2009-12-29	Domantis Ltd	Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
AU2005316524B2 (en)	2004-12-13	2012-01-12	Amylin Pharmaceuticals, Llc	Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same
WO2006069388A2 (en)	2004-12-21	2006-06-29	Nektar Therapeutics Al, Corporation	Stabilized polymeric thiol reagents
EP2168982A1 (en)	2004-12-22	2010-03-31	Eli Lilly & Company	GLP-1 analog fusion protein formulations
WO2006073890A2 (en)	2004-12-24	2006-07-13	Amylin Pharmaceuticals, Inc.	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
EP2505207B1 (en)	2005-01-14	2015-04-22	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
US8716221B2 (en)	2005-01-14	2014-05-06	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
US20080233053A1 (en)	2005-02-07	2008-09-25	Pharmalight Inc.	Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
SG159551A1 (en)	2005-02-11	2010-03-30	Amylin Pharmaceuticals Inc	Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
WO2006097535A2 (en)	2005-03-18	2006-09-21	Novo Nordisk A/S	Peptide agonists of the glucagon family with secretin like activity
US8946149B2 (en)	2005-04-11	2015-02-03	Amylin Pharmaceuticals, Llc	Use of exendin and analogs thereof to delay or prevent cardiac remodeling
CN101163514B (en)	2005-04-24	2012-01-25	诺和诺德公司	Injection device
WO2006125763A1 (en)	2005-05-25	2006-11-30	Novo Nordisk A/S	Stabilized polypeptide formulations
KR20080026117A (en)	2005-05-26	2008-03-24	브리스톨-마이어스 스큅 컴퍼니	N-terminal modified JP-1 receptor modulator
CN101217940B (en)	2005-06-06	2013-03-27	卡穆鲁斯公司	Glp-1 analogue formulations
ATE553124T1 (en)	2005-06-13	2012-04-15	Imp Innovations Ltd	OXYNTOMODULIN ANALOGS AND THEIR EFFECTS ON EATING BEHAVIOR
GB0511986D0 (en)	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
MX2007016314A (en)	2005-06-16	2008-03-10	Nektar Therapeutics Al Corp	Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates.
WO2007019331A2 (en)	2005-08-04	2007-02-15	Nektar Therapeutics Al, Corporation	Conjugates of a g-csf moiety and a polymer
CN101277722A (en)	2005-08-06	2008-10-01	王庆华	Composition and method for prevention and treatment of type I diabetes
EP2330124B1 (en)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
SI2347762T1 (en)	2005-08-19	2019-09-30	Amylin Pharmaceuticals, Llc	Exendin for treating diabetes and reducing body weight
KR101643478B1 (en)	2005-09-14	2016-07-27	맨카인드 코포레이션	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CA2622579C (en)	2005-09-20	2013-12-31	Novartis Ag	Use of a dpp-iv inhibitor to reduce hypoglycemic events
US8759290B2 (en)	2005-10-18	2014-06-24	Biocon Limited	Oral glucagon-like peptide conjugates for metabolic diseases
WO2007047922A2 (en)	2005-10-19	2007-04-26	Smartcells, Inc.	Polymer-drug conjugates
US8338368B2 (en)	2005-11-07	2012-12-25	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
WO2007053946A1 (en)	2005-11-09	2007-05-18	Conjuchem Biotechnologies Inc.	Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
WO2007064691A1 (en)	2005-12-02	2007-06-07	Nabil Habib Lab	Treatment of cancer and other diseases
BRPI0620586A2 (en)	2005-12-02	2011-11-16	Nastech Pharm Co	aqueous pharmaceutical formulation for intranasal administration and use of an aqueous pharmaceutical formulation to make a medicament
WO2007067964A2 (en)	2005-12-08	2007-06-14	Nastech Pharmaceutical Company Inc.	Mucosal delivery of stabilized formulations of exendin
EP2364735A3 (en)	2005-12-16	2012-04-11	Nektar Therapeutics	Branched PEG conjugates of GLP-1
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en)	2005-12-20	2007-06-28	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101400363B (en)	2006-01-18	2012-08-29	昌达生物科技公司	Pharmaceutical compositions with enhanced stability
EP1988922A4 (en)	2006-02-03	2010-06-02	Medimmune Llc	Protein formulations
US7704953B2 (en)	2006-02-17	2010-04-27	Mdrna, Inc.	Phage displayed cell binding peptides
JP5412273B2 (en)	2006-03-21	2014-02-12	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	Peptide-peptidase inhibitors and uses thereof
RU2419452C2 (en)	2006-04-13	2011-05-27	Ипсен Фарма С.А.С.	PHARMACEUTICAL COMPOSITIONS OF hGLP-1, EXENDIN-4 AND THEIR ANALOGUES
CN104288756A (en)	2006-04-14	2015-01-21	曼金德公司	Glucagon-like peptide 1 (GLP-1) pharmaceutical formulations
PE20080251A1 (en)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	USES OF DPP IV INHIBITORS
EP2029160A2 (en)	2006-05-12	2009-03-04	Amylin Pharmaceuticals, Inc.	Methods to restore glycemic control
EP2021014A1 (en)	2006-05-26	2009-02-11	Brystol-Myers Squibb Company	Sustained release glp-1 receptor modulators
MX2008015107A (en)	2006-05-26	2008-12-09	Amylin Pharmaceuticals Inc	Composition and methods for treatment of congestive heart failure.
ES2401856T3 (en)	2006-06-21	2013-04-25	Biocon Limited	A method to produce a biologically active polypeptide that has insulinotropic activity
EP2494959B1 (en)	2006-07-05	2014-11-19	Foamix Ltd.	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
CN101511868B (en)	2006-07-24	2013-03-06	比奥雷克西斯制药公司	Exendin fusion proteins
US7928186B2 (en)	2006-08-02	2011-04-19	Phoenix Pharmaceuticals, Inc.	Cell permeable bioactive peptide conjugates
WO2008016729A1 (en)	2006-08-04	2008-02-07	Nastech Pharmaceutical Company Inc.	Compositions for intranasal delivery of human insulin and uses thereof
EP3421031A1 (en)	2006-08-09	2019-01-02	Intarcia Therapeutics, Inc	Osmotic delivery systems and piston assemblies
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008021560A2 (en)	2006-08-17	2008-02-21	Amylin Pharmaceuticals, Inc.	Dpp-iv resistant gip hybrid polypeptides with selectable properties
US20090318353A1 (en) *	2006-08-25	2009-12-24	Novo Nordisk A/S	Acylated Exendin-4 Compounds
CN101125207B (en)	2006-11-14	2012-09-05	上海华谊生物技术有限公司	Exendin or its analogs with polyethylene group and its preparation and application
CN101605530A (en)	2006-12-12	2009-12-16	安米林药品公司	Pharmaceutical preparation and its preparation method
TWI428346B (en)	2006-12-13	2014-03-01	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
ES2628063T3 (en)	2007-01-05	2017-08-01	Indiana University Research And Technology Corporation	Glucagon analogs showing greater solubility in physiological pH buffers
RU2432361C2 (en)	2007-01-05	2011-10-27	КовЭкс Текнолоджиз Айэлэнд Лимитед	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101663317A (en) *	2007-01-05	2010-03-03	CovX科技爱尔兰有限公司	glucagon-like protein-1 receptor (glp-1r) agonist compounds
US20090098130A1 (en) *	2007-01-05	2009-04-16	Bradshaw Curt W	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2008098212A2 (en)	2007-02-08	2008-08-14	Diobex, Inc.	Extended release formulations of glucagon and other peptides and proteins
EP2111414B1 (en)	2007-02-15	2014-07-02	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
US8420598B2 (en)	2007-04-20	2013-04-16	B & L Delipharm Corp.	Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
CN105688191A (en)	2007-04-23	2016-06-22	精达制药公司	Suspension formulations of insulinotropic peptides and uses thereof
WO2008134425A1 (en)	2007-04-27	2008-11-06	Cedars-Sinai Medical Center	Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US7829664B2 (en)	2007-06-01	2010-11-09	Boehringer Ingelheim International Gmbh	Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
CA2689909C (en)	2007-06-08	2016-04-05	Ascendis Pharma As	Long-acting polymeric prodrugs of exendin
DK2158214T3 (en)	2007-06-15	2011-12-05	Zealand Pharma As	Glucagon analogues
WO2009009562A2 (en)	2007-07-10	2009-01-15	Eli Lilly And Company	Glp-1-fc fusion protein formulation
EP2185178B1 (en)	2007-08-03	2017-08-23	Eli Lilly And Company	Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN101366692A (en)	2007-08-15	2009-02-18	江苏豪森药业股份有限公司	Stable Exenatide formulation
NZ599755A (en)	2007-08-30	2013-08-30	Curedm Group Holdings Llc	Compositions and methods of using proislet peptides and analogs thereof
ES2532116T3 (en)	2007-09-05	2015-03-24	Novo Nordisk A/S	Peptides derived with A-B-C-D and their therapeutic uses
US20100256056A1 (en)	2007-09-07	2010-10-07	Zheng Xin Dong	Analogues of exendin-4 and exendin-3
AU2008316634B2 (en)	2007-10-24	2014-02-27	Mannkind Corporation	Method of preventing adverse effects by GLP-1
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
CN101969928B (en)	2007-10-24	2014-05-07	曼金德公司	Delivery of active agents
JP5669582B2 (en)	2007-10-30	2015-02-12	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Glucagon antagonist
MX2010004298A (en)	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compounds exhibiting glucagon antagonist and glp-1 agonist activity.
PL2209800T3 (en)	2007-11-16	2013-12-31	Novo Nordisk As	Stable pharmaceutical compositions comprising liraglutide and degludec
EP2224945B1 (en)	2007-11-23	2012-05-16	Michael Rothkopf	Methods of enhancing diabetes resolution
CN101444618B (en)	2007-11-26	2012-06-13	杭州九源基因工程有限公司	Pharmaceutical preparation containing exenatide
JP2011506442A (en)	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	Formulation of insulinotropic peptide conjugate
AU2009203809B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
US20110065633A1 (en)	2008-01-30	2011-03-17	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
EP2237799B1 (en)	2008-02-01	2019-04-10	Ascendis Pharma A/S	Prodrug comprising a self-cleavable linker
MX349413B (en)	2008-02-06	2017-07-19	Biocon Ltd	Fermentation media comprising urea-like nitrogen sources and its use for the production of secondary metabolits, enzymes and recombinant proteias.
WO2009114959A1 (en)	2008-03-20	2009-09-24	中国人民解放军军事医学科学院毒物药物研究所	Injectalble sustained-release pharmaceutical formulation and method for preparing it
AU2008354530B2 (en)	2008-04-07	2014-02-27	Indian Institute Of Science	Compositions useful for the treatment of diabetes and other chronic disorder
EP2288368A1 (en)	2008-05-07	2011-03-02	Merrion Research III Limited	Compositions of peptides and processes of preparation thereof
ES2552646T3 (en)	2008-05-21	2015-12-01	Amylin Pharmaceuticals, Inc.	Exendins to lower cholesterol and triglycerides
WO2009143014A1 (en)	2008-05-23	2009-11-26	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist bioassays
CA2982550C (en)	2008-06-13	2020-08-25	Mannkind Corporation	A dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
PA8830501A1 (en)	2008-06-17	2010-07-27	Univ Indiana Res & Tech Corp	GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
AU2009274425B2 (en)	2008-06-17	2014-05-15	Indiana University Research And Technology Corporation	GIP-based mixed agonists for treatment of metabolic disorders and obesity
BRPI0914889A2 (en)	2008-06-17	2015-11-24	Otsuka Chemical Co Ltd	oligosaccharide chain added glp-1 peptide
RU2560254C2 (en)	2008-06-17	2015-08-20	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES
CA2726894A1 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
US20110129522A1 (en)	2008-07-21	2011-06-02	Transpharma Medical Ltd.	Transdermal system for extended delivery of incretins and incretn mimetic peptides
WO2010013012A2 (en)	2008-08-01	2010-02-04	Lund University Bioscience Ab	Novel polypeptides and uses thereof
CN101670096B (en)	2008-09-11	2013-01-16	杭州九源基因工程有限公司	Medicinal preparation containing exenatide
KR101939557B1 (en)	2008-10-17	2019-01-17	사노피-아벤티스 도이칠란트 게엠베하	Combination of an insulin and a GLP-1 agonist
HUE031900T2 (en)	2008-12-10	2017-08-28	Glaxosmithkline Llc	Pharmaceutical compositions of albiglutide
EP2370460B1 (en)	2008-12-15	2014-04-30	Zealand Pharma A/S	Glucagon analogues
AP2011005774A0 (en)	2008-12-15	2011-06-30	Zealand Pharma As	Glucagon analogues.
EA020596B1 (en)	2008-12-15	2014-12-30	Зилэнд Фарма А/С	Glucagon analogues
WO2010070253A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2010071807A1 (en)	2008-12-19	2010-06-24	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
CN101538323B (en)	2009-01-13	2012-05-09	深圳翰宇药业股份有限公司	Method for purifying Exenatide
DE102009006602A1 (en)	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
AU2010221254B2 (en)	2009-03-04	2014-04-03	Mannkind Corporation	An improved dry powder drug delivery system
WO2010100241A1 (en)	2009-03-05	2010-09-10	Sanofi-Aventis Deutschland Gmbh	Drug delivery device with retractable needle
EP2413955A4 (en)	2009-04-01	2012-12-26	Amylin Pharmaceuticals Inc	AGONIST COMPOUNDS OF GLP-1 RECEPTORS HAVING CONFORMATIONAL CONSTRAINTS AT THEIR N-TERMINAL END
US8992886B2 (en)	2009-04-06	2015-03-31	Board Of Regents, The University Of Texas System	Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
JP5727459B2 (en)	2009-04-22	2015-06-03	アルテオゼン，インクＡｌｔｅｏｇｅｎ，Ｉｎｃ	Protein or peptide fusion with increased half-life in the body by maintaining body persistence
CN101870728A (en)	2009-04-23	2010-10-27	派格生物医药(苏州)有限公司	Novel Exendin variant and conjugate thereof
CN101559041B (en)	2009-05-19	2014-01-15	中国科学院过程工程研究所	Polypeptide drug sustained-release microsphere or microcapsule preparation with uniform particle size and preparation method
AU2010251140B2 (en)	2009-05-20	2015-01-29	Sanofi-Aventis Deutschland Gmbh	A bung for drug containing cartridges in drug delivery devices
EP2432527B1 (en)	2009-05-20	2019-10-02	Sanofi-Aventis Deutschland GmbH	A system comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
EP2435061A4 (en)	2009-05-28	2013-03-27	Amylin Pharmaceuticals Inc	AGONIST COMPOUNDS OF GLP-1 RECEPTOR FOR IMPROVING SLEEP
JP2012529463A (en)	2009-06-11	2012-11-22	ノヴォノルディスクアー／エス	Combination of GLP-1 and FGF21 for treating type 2 diabetes
KR20120087875A (en)	2009-06-16	2012-08-07	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	Gip receptor-active glucagon compounds
EP2448965A4 (en)	2009-07-02	2015-02-11	Angiochem Inc	Multimeric peptide conjugates and uses thereof
CA2767792A1 (en)	2009-07-13	2011-01-20	Zealand Pharma A/S	Acylated glucagon analogues
CN101601646B (en)	2009-07-22	2011-03-23	南京凯瑞尔纳米生物技术有限公司	Nasal cavity drop for treating diabetes and preparation method thereof
WO2011011675A1 (en)	2009-07-23	2011-01-27	Zelos Therapeutics, Inc.	Pharmaceutically acceptable formulations/compositions for peptidyl drugs
MX2012001399A (en)	2009-07-31	2012-03-21	Sanofi Aventis Deutschland	Prodrugs comprising an insulin linker conjugate.
WO2011017835A1 (en)	2009-08-11	2011-02-17	Nanjing University	Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CN101993485B (en)	2009-08-20	2013-04-17	重庆富进生物医药有限公司	Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
CN102666586A (en)	2009-09-30	2012-09-12	葛兰素集团有限公司	Drug fusions and conjugates with extended half life
US20110097386A1 (en)	2009-10-22	2011-04-28	Biodel, Inc.	Stabilized glucagon solutions
US9610329B2 (en)	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
WO2011049713A2 (en)	2009-10-22	2011-04-28	Biodel Inc.	Stabilized glucagon solutions
AU2010312655A1 (en)	2009-10-30	2012-05-03	Glytech, Inc.	Glycosylated form of antigenic GLP-1 analogue
DK2496583T3 (en)	2009-11-02	2015-02-02	Pfizer	Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011056713A2 (en)	2009-11-03	2011-05-12	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist compounds for obstructive sleep apnea
AU2010317994B2 (en)	2009-11-13	2014-03-06	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10029011B2 (en)	2009-11-13	2018-07-24	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
EP2512470B1 (en)	2009-12-15	2016-11-30	Octeta Therapeutics, LLC	Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CA2783264A1 (en)	2009-12-15	2011-07-14	Metabolic Solutions Development Company, Llc	Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
AU2010340055B2 (en)	2009-12-15	2014-07-24	Cirius Therapeutics, Inc.	PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
WO2011084459A1 (en)	2009-12-15	2011-07-14	Metabolic Solutions Development Company	Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
PT2513140E (en)	2009-12-16	2016-03-11	Novo Nordisk As	Double-acylated glp-1 derivatives
CN102933200B (en)	2009-12-18	2015-11-25	莱迪杜德制药公司	Comprise the single-phase gels compositions of phospholipid
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
CN101798588B (en) *	2009-12-21	2015-09-09	上海仁会生物制药股份有限公司	GLP-1 receptor stimulant Determination of biological activity method
AR079344A1 (en)	2009-12-22	2012-01-18	Lilly Co Eli	PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Oxyntomodulin peptide analogue ‎
CA2786934A1 (en)	2010-01-20	2011-07-28	Zealand Pharma A/S	Treatment of cardiac conditions
BR112012018585A2 (en) *	2010-01-27	2017-01-10	Univ Indiana Res & Tech Corp	antagonist-gon agonist glucagon compositions and compositions for the treatment of metabolic disorders and obesity
TR201902092T4 (en)	2010-02-01	2019-03-21	Sanofi Aventis Deutschland	A method of fixing a cartridge in a cartridge holder, a drug delivery device, and a cartridge holder.
WO2011109784A1 (en)	2010-03-05	2011-09-09	Conjuchem, Llc	Formulation of insulinotropic peptide conjugates
CN102917748B (en)	2010-03-24	2015-04-01	施菲姆德控股有限责任公司	Intravascular tissue disruption
AR080592A1 (en) *	2010-03-26	2012-04-18	Lilly Co Eli	PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
US20130143798A1 (en)	2010-03-26	2013-06-06	Novo Nordisk A/S	Novel glucagon analogues
ES2661228T3 (en)	2010-05-13	2018-03-28	Indiana University Research And Technology Corporation	Glucagon superfamily peptides that show nuclear hormone receptor activity
BR112012028707A2 (en)	2010-05-13	2019-09-24	Univ Indiana Res & Tech Corp	glucagon compound of the peptide superfamily exhibiting g receptor activity with coupled protein, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof.
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
BR112012029280A2 (en)	2010-05-20	2016-11-29	Glaxo Group Ltd	serum antialbumin immunoglobulin single variable domain variant, anti-sa immunoglobulin, multispecific ligand, fusion protein, composition, nucleic acid, vector, isolated host cell, and use of one variant, multispecific ligand or fusion protein
WO2011156407A2 (en)	2010-06-09	2011-12-15	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonists to treat pancre-atitis
CN101891823B (en)	2010-06-11	2012-10-03	北京东方百泰生物科技有限公司	Exendin-4 and analog fusion protein thereof
US8636711B2 (en)	2010-06-14	2014-01-28	Legacy Emanuel Hospital & Health Center	Stabilized glucagon solutions and uses therefor
CA2801936C (en)	2010-06-21	2021-06-01	Mannkind Corporation	Dry powder drug delivery system and methods
AR081975A1 (en)	2010-06-23	2012-10-31	Zealand Pharma As	GLUCAGON ANALOGS
CA2796894A1 (en)	2010-06-24	2011-12-29	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
WO2011162830A2 (en)	2010-06-24	2011-12-29	Biousian Biosystems, Inc.	Glucagon-like peptide-1 glycopeptides
WO2011163473A1 (en)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
US20120046225A1 (en)	2010-07-19	2012-02-23	The Regents Of The University Of Colorado, A Body Corporate	Stable glucagon formulations for the treatment of hypoglycemia
WO2012012352A2 (en)	2010-07-19	2012-01-26	Amidebio, Llc	Modified peptides and proteins
AU2011282745A1 (en)	2010-07-28	2013-03-14	Amylin Pharmaceuticals, Llc	GLP-1 receptor agonist compounds having stabilized regions
CN102397558B (en)	2010-09-09	2013-08-14	中国人民解放军军事医学科学院毒物药物研究所	Positioning pegylation modified compound of Exendin-4 analog and application thereof
EP2438930A1 (en)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrugs comprising an exendin linker conjugate
WO2012050923A2 (en)	2010-09-28	2012-04-19	Amylin Pharmaceuticals, Inc.	Engineered polypeptides having enhanced duration of action
WO2012059764A1 (en)	2010-11-03	2012-05-10	Arecor Limited	Novel composition comprising glucagon
JP6092113B2 (en)	2010-11-09	2017-03-08	マンカインドコーポレイション	Composition for the treatment of migraine comprising serotonin receptor agonist and diketopiperazine
EP2460552A1 (en)	2010-12-06	2012-06-06	Sanofi-Aventis Deutschland GmbH	Drug delivery device with locking arrangement for dose button
CN102552883B (en)	2010-12-09	2014-02-19	天津药物研究院	Polypeptide compound, pharmaceutical composition, its preparation method and application thereof
SMT201800117T1 (en)	2010-12-16	2018-05-02	Novo Nordisk As	Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
ES2713952T3 (en)	2010-12-22	2019-05-24	Univ Indiana Res & Tech Corp	Glucagon analogs showing GIP receptor activity
US9161953B2 (en)	2010-12-22	2015-10-20	Amylin Pharmaceuticals, Llc	GLP-1 receptor agonists for islet cell transplantation
CN102532301B (en)	2010-12-31	2014-09-03	上海医药工业研究院	Novel Exendin-4 analogues and preparation method thereof
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102100906A (en)	2011-02-18	2011-06-22	深圳翰宇药业股份有限公司	Medicinal preparation of exenatide and preparation method thereof
DK2683364T3 (en)	2011-03-10	2017-02-27	Xeris Pharmaceuticals Inc	Stable formulations for parenteral injection of peptide drugs.
CN102718858B (en)	2011-03-29	2014-07-02	天津药物研究院	Glucagon-like peptide-1 (GLP-1) analogue monomer and dimer, preparation method therefor and application thereof
CN106928341B (en)	2011-03-30	2021-06-01	上海仁会生物制药股份有限公司	Fixed-point mono-substituted pegylated Exendin analogue and preparation method thereof
US9790262B2 (en)	2011-04-05	2017-10-17	Longevity Biotech, Inc.	Compositions comprising glucagon analogs and methods of making and using the same
WO2012140647A2 (en)	2011-04-11	2012-10-18	Yeda Research And Development Co. Ltd	Albumin binding probes and drug conjugates thereof
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
CN102766204B (en)	2011-05-05	2014-10-15	天津药物研究院	Glucagon-like peptide-1 mutant polypeptide, its preparation method and application thereof
KR20240110072A (en)	2011-05-18	2024-07-12	메더리스 다이어비티즈, 엘엘씨	Improved peptide pharmaceuticals for insulin resistance
WO2012162547A2 (en)	2011-05-25	2012-11-29	Amylin Pharmaceuticals, Inc.	Long duration dual hormone conjugates
UA113626C2 (en)	2011-06-02	2017-02-27		A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
CA2838503C (en)	2011-06-10	2020-02-18	Hanmi Science Co., Ltd.	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
EP2718317B1 (en)	2011-06-10	2018-11-14	Beijing Hanmi Pharmaceutical Co., Ltd.	Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
MX340172B (en)	2011-06-17	2016-06-28	Halozyme Inc	Stable formulations of a hyaluronan-degrading enzyme.
PL2721062T3 (en)	2011-06-17	2019-05-31	Hanmi Science Co Ltd	A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
HUE035776T2 (en)	2011-06-22	2018-05-28	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists
MX2013015168A (en)	2011-06-22	2014-03-31	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists.
JP2014520159A (en)	2011-06-24	2014-08-21	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	Method for treating diabetes with sustained-release preparation of GLP-1 receptor agonist
KR101357117B1 (en)	2011-06-28	2014-02-06	비앤엘델리팜 주식회사	PEGylated Exendin-4 analogues or its derivatives, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes
JP6396211B2 (en)	2011-07-04	2018-09-26	インペリアル・イノベイションズ・リミテッド	New compounds and their effects on feeding behavior
JP6006309B2 (en)	2011-07-08	2016-10-12	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	Engineered polypeptides with increased duration of action and reduced immunogenicity
EP3053590A1 (en)	2011-08-10	2016-08-10	Adocia	Injectable solution of at least one type of basal insulin
JP6169079B2 (en)	2011-08-24	2017-07-26	フェーズバイオファーマシューティカルズ，インコーポレイテッド	Formulation of active agent for sustained release
WO2013029279A1 (en)	2011-09-03	2013-03-07	深圳市健元医药科技有限公司	Novel glp-i analogue, preparation method and use thereof
AR088161A1 (en)	2011-09-23	2014-05-14	Novo Nordisk As	GLUCAGON ANALOGS
CA2851690C (en)	2011-10-28	2022-07-26	Sanofi-Aventis Deutschland Gmbh	Treatment protocol of diabetes type 2
CN102363633B (en)	2011-11-16	2013-11-20	天津拓飞生物科技有限公司	Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof
MX2014003579A (en)	2011-11-17	2015-04-10	Univ Indiana Res & Tech Corp	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity.
JP5819005B2 (en)	2011-11-29	2015-11-18	ジュロックスプロプライエタリーリミテッド	Pharmaceutical composition
EP2791160B1 (en)	2011-12-16	2022-03-02	ModernaTX, Inc.	Modified mrna compositions
ES2623786T3 (en)	2011-12-22	2017-07-12	Pfizer Inc.	Purification procedure of an H38C2 antibody sample
EA201490982A1 (en)	2011-12-23	2015-01-30	Зилэнд Фарма А/С	ANALOGUE GLUACAGONA
JP2015503565A (en)	2011-12-29	2015-02-02	ラティチュードファーマシューティカルズインコーポレイテッドＬａｔｉｔｕｄｅＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Stabilized glucagon nanoemulsion
WO2013104861A1 (en)	2012-01-09	2013-07-18	Adocia	Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
WO2013148871A1 (en)	2012-03-28	2013-10-03	Amylin Pharmaceuticals, Llc	Engineered polypeptides
WO2013148966A1 (en)	2012-03-28	2013-10-03	Amylin Pharmaceuticals, Llc	Transmucosal delivery of engineered polypeptides
AU2013243949A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
JP2015513913A (en)	2012-04-02	2015-05-18	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Modified polynucleotide
CN102649947A (en)	2012-04-20	2012-08-29	无锡和邦生物科技有限公司	Cell strain for measuring bioactivity of GLP-1 and functional analogue thereof and application of cell strain
US20150111246A1 (en)	2012-04-24	2015-04-23	Astrazeneca Pharmaceuticals Lp	Site-specific enzymatic modification of exendins and analogs thereof
US20130289241A1 (en)	2012-04-26	2013-10-31	Shanghai Ambiopharm, Inc.	Method for preparing exenatide
WO2013182217A1 (en)	2012-04-27	2013-12-12	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
US8901484B2 (en)	2012-04-27	2014-12-02	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
CN104540850B (en)	2012-05-03	2018-05-18	西兰制药公司	Glucagon-like peptide 2 (GLP-2) analog
EP2844669B1 (en) *	2012-05-03	2018-08-01	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EP2664374A1 (en)	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
CN103421094A (en)	2012-05-24	2013-12-04	上海医药工业研究院	Polypeptide compound with EPO-like activity
US20150174209A1 (en)	2012-05-25	2015-06-25	Amylin Pharmaceuticals. Llc	Insulin-pramlintide compositions and methods for making and using them
CA2875743A1 (en)	2012-06-14	2013-12-19	Sanofi	Exendin-4 peptide analogues
EP2864350B1 (en)	2012-06-21	2018-03-28	Indiana University Research and Technology Corporation	Analogs of glucagon exhibiting gip receptor activity
CN104583232B (en)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	Show the glucagon analogs of GIP receptor actives
EP2872205B1 (en)	2012-07-12	2017-02-08	MannKind Corporation	Dry powder drug delivery systems
IN2015DN00544A (en)	2012-07-23	2015-06-26	Zealand Pharma As
AR092862A1 (en)	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
AR094821A1 (en)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
KR101968344B1 (en)	2012-07-25	2019-04-12	한미약품 주식회사	A composition for treating hyperlipidemia comprising oxyntomodulin analog
WO2014027254A1 (en)	2012-08-14	2014-02-20	Wockhardt Limited	Pharmaceutical microparticulate compositions of polypeptides
EP2934562A1 (en)	2012-08-14	2015-10-28	Wockhardt Limited	Pharmaceutical microparticulate compositions of polypeptides
CN102816244A (en)	2012-08-23	2012-12-12	无锡和邦生物科技有限公司	Fusion protein of exendin-4 peptide and human serum albumin (HSA) and preparation method thereof
CN102827270A (en)	2012-09-13	2012-12-19	无锡和邦生物科技有限公司	Pegylated exenatide ramification and use thereof
TWI608013B (en)	2012-09-17	2017-12-11	西蘭製藥公司	Glucagon analogues
US9546205B2 (en)	2012-09-17	2017-01-17	Imperial Innovations Limited	Peptide analogues of glucagon and GLP1
WO2014049610A2 (en)	2012-09-26	2014-04-03	Cadila Healthcare Limited	Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
JP6363612B2 (en)	2012-11-06	2018-07-25	ハンミファーマシューティカルカンパニーリミテッド	Liquid preparation of protein conjugate comprising oxyntomodulin and immunoglobulin fragment
KR101993393B1 (en)	2012-11-06	2019-10-01	한미약품 주식회사	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
BR112015011478B1 (en)	2012-11-20	2022-10-25	Mederis Diabetes, Llc	PEPTIDE PRODUCTS, THEIR USES AND PHARMACEUTICAL COMPOSITION
TWI674270B (en)	2012-12-11	2019-10-11	英商梅迪繆思有限公司	Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201503524PA (en)	2012-12-21	2015-06-29	Sanofi Sa	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103908657A (en)	2012-12-31	2014-07-09	复旦大学附属华山医院	Use of glucagons-like peptide-1 analogue in preparation of ophthalmic disease drug
US9714277B2 (en)	2013-03-14	2017-07-25	Medimmune Limited	Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
RU2678134C2 (en)	2013-03-14	2019-01-23	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Insulin-incretin conjugates
US20160058881A1 (en)	2013-03-15	2016-03-03	Indiana University Research And Technology Corporation	Prodrugs with prolonged action
AU2014255608B2 (en)	2013-04-18	2018-01-25	Novo Nordisk A/S	Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
JP2014227368A (en)	2013-05-21	2014-12-08	国立大学法人帯広畜産大学	Glucagon analog for treating diabetes mellitus and hyperglycemia condition
CN103304660B (en)	2013-07-12	2016-08-10	上海昂博生物技术有限公司	A kind of synthetic method of Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37]
CN103405753B (en)	2013-08-13	2016-05-11	上海仁会生物制药股份有限公司	Stable insulin secretion accelerating peptide liquid drugs injection pharmaceutical composition
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
TWI666220B (en)	2013-10-17	2019-07-21	丹麥商西蘭製藥公司	Acylated glucagon analogues
US10131702B2 (en)	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
TW201609799A (en)	2013-12-13	2016-03-16	賽諾菲公司	Dual GLP-1/GIP receptor agonists
EP3080151A1 (en)	2013-12-13	2016-10-19	Sanofi	Exendin-4 peptide analogues
TW201609795A (en)	2013-12-13	2016-03-16	賽諾菲公司	EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080155A1 (en)	2013-12-13	2016-10-19	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
CN103665148B (en)	2013-12-17	2016-05-11	中国药科大学	A kind of Polypeptide-k of Orally-administrable and method for making thereof and purposes
CN103980358B (en)	2014-01-03	2016-08-31	杭州阿诺生物医药科技股份有限公司	A kind of method preparing Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37]
EP3091995B1 (en)	2014-01-09	2024-03-20	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
SG11201604708VA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
GB201404002D0 (en)	2014-03-06	2014-04-23	Imp Innovations Ltd	Novel compounds
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (en)	2014-09-23	2020-04-17	深圳市图微安创科技开发有限公司	Oxyntomodulin analogues
EP3204408B1 (en)	2014-10-10	2020-05-06	Novo Nordisk A/S	Stable glp-1 based glp-1/glucagon receptor co-agonists
TN2017000148A1 (en)	2014-10-24	2018-10-19	Merck Sharp & Dohme	Co-agonists of the glucagon and glp-1 receptors
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198604A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
TW201706291A (en)	2015-07-10	2017-02-16	賽諾菲公司	New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

2013
- 2013-12-19 SG SG11201503524PA patent/SG11201503524PA/en unknown
- 2013-12-19 KR KR1020157018591A patent/KR20150099548A/en not_active Application Discontinuation
- 2013-12-19 CN CN201380066471.6A patent/CN104870009B/en active Active
- 2013-12-19 HU HUE13811510A patent/HUE035803T2/en unknown
- 2013-12-19 RU RU2015129788A patent/RU2015129788A/en not_active Application Discontinuation
- 2013-12-19 PT PT138115100T patent/PT2934568T/en unknown
- 2013-12-19 RU RU2015129696A patent/RU2015129696A/en not_active Application Discontinuation
- 2013-12-19 SG SG11201503526UA patent/SG11201503526UA/en unknown
- 2013-12-19 AR ARP130104909A patent/AR099912A1/en unknown
- 2013-12-19 AU AU2013366692A patent/AU2013366692B2/en not_active Ceased
- 2013-12-19 LT LTEP13811510.0T patent/LT2934568T/en unknown
- 2013-12-19 HU HUE13810958A patent/HUE038748T2/en unknown
- 2013-12-19 JP JP2015548550A patent/JP2016506401A/en not_active Abandoned
- 2013-12-19 BR BR112015014800A patent/BR112015014800A2/en not_active Application Discontinuation
- 2013-12-19 EP EP18164271.1A patent/EP3400957A1/en not_active Withdrawn
- 2013-12-19 WO PCT/EP2013/077312 patent/WO2014096149A1/en active Application Filing
- 2013-12-19 CN CN201380067043.5A patent/CN104902920A/en active Pending
- 2013-12-19 KR KR1020157017459A patent/KR20150096433A/en not_active Application Discontinuation
- 2013-12-19 MX MX2015008079A patent/MX362190B/en active IP Right Grant
- 2013-12-19 CA CA2895875A patent/CA2895875A1/en not_active Abandoned
- 2013-12-19 WO PCT/EP2013/077313 patent/WO2014096150A1/en active Application Filing
- 2013-12-19 SG SG10201705097PA patent/SG10201705097PA/en unknown
- 2013-12-19 JP JP2015548552A patent/JP6391589B2/en active Active
- 2013-12-19 SI SI201330923T patent/SI2934568T1/en unknown
- 2013-12-19 PL PL13811510T patent/PL2934568T3/en unknown
- 2013-12-19 WO PCT/EP2013/077310 patent/WO2014096148A1/en active Application Filing
- 2013-12-19 JP JP2015548553A patent/JP2016503771A/en not_active Abandoned
- 2013-12-19 SG SG11201504215PA patent/SG11201504215PA/en unknown
- 2013-12-19 AU AU2013366691A patent/AU2013366691A1/en not_active Abandoned
- 2013-12-19 EP EP13810957.4A patent/EP2934566B1/en active Active
- 2013-12-19 RS RS20180942A patent/RS57531B1/en unknown
- 2013-12-19 SI SI201331127T patent/SI2934567T1/en unknown
- 2013-12-19 MA MA38276A patent/MA38276B1/en unknown
- 2013-12-19 KR KR1020157017458A patent/KR20150096684A/en not_active Application Discontinuation
- 2013-12-19 CA CA2895755A patent/CA2895755A1/en not_active Abandoned
- 2013-12-19 AR ARP130104911A patent/AR094178A1/en unknown
- 2013-12-19 ES ES13810958.2T patent/ES2688367T3/en active Active
- 2013-12-19 UA UAA201507199A patent/UA116553C2/en unknown
- 2013-12-19 AR ARP130104914A patent/AR094181A1/en unknown
- 2013-12-19 BR BR112015013809A patent/BR112015013809A2/en active Search and Examination
- 2013-12-19 EP EP13814892.9A patent/EP2934569A1/en not_active Withdrawn
- 2013-12-19 AU AU2013366690A patent/AU2013366690B2/en not_active Ceased
- 2013-12-19 PE PE2015001035A patent/PE20151239A1/en unknown
- 2013-12-19 CN CN201380067038.4A patent/CN104902919B/en not_active Expired - Fee Related
- 2013-12-19 PL PL13810958T patent/PL2934567T3/en unknown
- 2013-12-19 CA CA2895156A patent/CA2895156A1/en not_active Abandoned
- 2013-12-19 KR KR1020157015384A patent/KR20150096398A/en not_active Application Discontinuation
- 2013-12-19 ES ES13811510.0T patent/ES2653765T3/en active Active
- 2013-12-19 JP JP2015548554A patent/JP6408998B2/en not_active Expired - Fee Related
- 2013-12-19 EA EA201591174A patent/EA031428B1/en not_active IP Right Cessation
- 2013-12-19 DK DK13810958.2T patent/DK2934567T3/en active
- 2013-12-19 EP EP13811510.0A patent/EP2934568B1/en active Active
- 2013-12-19 PT PT13810958T patent/PT2934567T/en unknown
- 2013-12-19 DK DK13811510.0T patent/DK2934568T3/en active
- 2013-12-19 MX MX2015008114A patent/MX2015008114A/en unknown
- 2013-12-19 LT LTEP13810958.2T patent/LT2934567T/en unknown
- 2013-12-19 WO PCT/EP2013/077307 patent/WO2014096145A1/en active Application Filing
- 2013-12-19 SG SG11201503576XA patent/SG11201503576XA/en unknown
- 2013-12-19 EP EP13810958.2A patent/EP2934567B9/en active Active
- 2013-12-19 CN CN201380066991.7A patent/CN104902918A/en active Pending
- 2013-12-19 AR ARP130104913A patent/AR094180A1/en unknown
- 2013-12-19 MX MX2015008099A patent/MX360317B/en active IP Right Grant
- 2013-12-19 MX MX2015008077A patent/MX2015008077A/en unknown
- 2013-12-19 BR BR112015014510A patent/BR112015014510A2/en not_active Application Discontinuation
- 2013-12-19 RU RU2015129815A patent/RU2652783C2/en not_active IP Right Cessation
- 2013-12-19 CA CA2894765A patent/CA2894765A1/en not_active Abandoned
- 2013-12-19 AU AU2013360721A patent/AU2013360721A1/en not_active Abandoned
- 2013-12-20 US US14/136,061 patent/US9745360B2/en active Active
- 2013-12-20 TW TW102147362A patent/TW201441252A/en unknown
- 2013-12-20 TW TW102147359A patent/TW201441251A/en unknown
- 2013-12-20 UY UY0001035233A patent/UY35233A/en not_active Application Discontinuation
- 2013-12-20 TW TW102147363A patent/TWI600663B/en not_active IP Right Cessation
- 2013-12-20 UY UY0001035232A patent/UY35232A/en not_active Application Discontinuation
- 2013-12-20 US US14/135,801 patent/US9670261B2/en active Active
- 2013-12-20 TW TW102147360A patent/TWI602828B/en not_active IP Right Cessation
- 2013-12-20 US US14/135,756 patent/US20140206608A1/en not_active Abandoned
- 2013-12-20 UY UY0001035234A patent/UY35234A/en not_active Application Discontinuation
- 2013-12-20 US US14/135,772 patent/US20140213513A1/en not_active Abandoned
- 2013-12-20 UY UY0001035231A patent/UY35231A/en not_active Application Discontinuation
2015
- 2015-05-04 IL IL238623A patent/IL238623A0/en unknown
- 2015-05-05 IL IL238650A patent/IL238650A0/en unknown
- 2015-05-07 IL IL238692A patent/IL238692A0/en unknown
- 2015-05-29 ZA ZA2015/03914A patent/ZA201503914B/en unknown
- 2015-05-31 IL IL239101A patent/IL239101A0/en unknown
- 2015-06-05 PH PH12015501291A patent/PH12015501291B1/en unknown
- 2015-06-18 CL CL2015001751A patent/CL2015001751A1/en unknown
- 2015-06-18 DO DO2015000156A patent/DOP2015000156A/en unknown
- 2015-06-18 TN TNP2015000283A patent/TN2015000283A1/en unknown
- 2015-07-08 CR CR20150358A patent/CR20150358A/en unknown
- 2015-07-20 EC ECIEPI201531141A patent/ECSP15031141A/en unknown
- 2015-12-09 HK HK15112144.3A patent/HK1211233A1/en not_active IP Right Cessation
- 2015-12-09 HK HK15112143.4A patent/HK1211232A1/en unknown
- 2015-12-09 HK HK15112142.5A patent/HK1211231A1/en unknown
2016
- 2016-02-11 HK HK16101474.5A patent/HK1213483A1/en unknown
- 2016-07-22 AR ARP160102245A patent/AR105816A2/en unknown
- 2016-08-31 CL CL2016002182A patent/CL2016002182A1/en unknown
2017
- 2017-04-12 US US15/486,054 patent/US10253079B2/en active Active
2018
- 2018-01-17 CY CY20181100056T patent/CY1120030T1/en unknown
- 2018-01-17 HR HRP20180092TT patent/HRP20180092T1/en unknown
- 2018-08-09 HR HRP20181300TT patent/HRP20181300T1/en unknown
- 2018-08-09 CY CY20181100833T patent/CY1121153T1/en unknown

Also Published As

Publication number	Publication date
SI2934567T1 (en)	2018-10-30
HRP20181300T1 (en)	2018-10-05
US10253079B2 (en)	2019-04-09
AU2013366690B2 (en)	2018-02-08
PE20151239A1 (en)	2015-09-08
PH12015501291A1 (en)	2015-08-24
EA201591174A1 (en)	2016-03-31
HK1211232A1 (en)	2016-05-20
HUE038748T2 (en)	2018-11-28
WO2014096150A1 (en)	2014-06-26
MA38276A1 (en)	2017-06-30
EP2934567B9 (en)	2018-08-22
JP2016503771A (en)	2016-02-08
UY35232A (en)	2014-07-31
EP2934566B1 (en)	2017-06-21
US20140221281A1 (en)	2014-08-07
RU2015129788A (en)	2017-01-30
CY1120030T1 (en)	2018-12-12
US20140206609A1 (en)	2014-07-24
IL238623A0 (en)	2015-06-30
EP2934567A1 (en)	2015-10-28
CY1121153T1 (en)	2020-05-29
EP2934566A1 (en)	2015-10-28
CL2015001751A1 (en)	2015-09-21
CN104870009B (en)	2021-05-18
AR099912A1 (en)	2016-08-31
MA38276B1 (en)	2018-03-30
CN104902920A (en)	2015-09-09
KR20150096398A (en)	2015-08-24
TW201441252A (en)	2014-11-01
UY35231A (en)	2014-07-31
JP2016503772A (en)	2016-02-08
CA2894765A1 (en)	2014-06-26
TW201429985A (en)	2014-08-01
UA116553C2 (en)	2018-04-10
RU2015129696A (en)	2017-01-27
DK2934568T3 (en)	2018-01-22
TW201443080A (en)	2014-11-16
CN104902918A (en)	2015-09-09
US20140206608A1 (en)	2014-07-24
ES2688367T3 (en)	2018-11-02
MX2015008099A (en)	2016-04-25
AR094178A1 (en)	2015-07-15
CR20150358A (en)	2015-09-16
PT2934568T (en)	2018-01-04
CN104870009A (en)	2015-08-26
US9745360B2 (en)	2017-08-29
JP6408998B2 (en)	2018-10-17
EP2934568A1 (en)	2015-10-28
ECSP15031141A (en)	2015-11-30
WO2014096145A1 (en)	2014-06-26
RU2015129815A (en)	2017-01-27
KR20150096433A (en)	2015-08-24
EP2934568B1 (en)	2017-10-18
HRP20180092T1 (en)	2018-02-23
UY35234A (en)	2014-07-31
JP6391589B2 (en)	2018-09-19
PH12015501291B1 (en)	2020-06-05
ZA201503914B (en)	2016-12-21
TN2015000283A1 (en)	2016-10-03
LT2934568T (en)	2018-02-12
AU2013366692B2 (en)	2017-11-23
PT2934567T (en)	2018-10-01
CN104902919B (en)	2018-11-20
BR112015013809A2 (en)	2017-11-14
BR112015014800A2 (en)	2017-10-10
PL2934567T3 (en)	2018-10-31
RS57531B1 (en)	2018-10-31
SG11201503526UA (en)	2015-06-29
AU2013366691A1 (en)	2015-07-09
LT2934567T (en)	2018-09-10
ES2653765T3 (en)	2018-02-08
WO2014096149A1 (en)	2014-06-26
HUE035803T2 (en)	2018-05-28
EP3400957A1 (en)	2018-11-14
MX2015008079A (en)	2015-10-30
IL239101A0 (en)	2015-07-30
IL238650A0 (en)	2015-06-30
AU2013366692A1 (en)	2015-07-09
HK1211231A1 (en)	2016-05-20
PL2934568T3 (en)	2018-03-30
US20170216406A1 (en)	2017-08-03
JP2016503770A (en)	2016-02-08
DOP2015000156A (en)	2015-08-31
AR094181A1 (en)	2015-07-15
CA2895156A1 (en)	2014-06-26
HK1211233A1 (en)	2016-05-20
CN104902919A (en)	2015-09-09
MX2015008114A (en)	2015-11-06
CA2895755A1 (en)	2014-06-26
CA2895875A1 (en)	2014-06-26
SG11201503576XA (en)	2015-06-29
SI2934568T1 (en)	2018-03-30
UY35233A (en)	2014-07-31
TW201441251A (en)	2014-11-01
BR112015014510A2 (en)	2017-11-21
WO2014096148A1 (en)	2014-06-26
DK2934567T3 (en)	2018-08-13
AU2013360721A1 (en)	2015-07-09
AU2013366690A1 (en)	2015-07-09
EP2934569A1 (en)	2015-10-28
MX2015008077A (en)	2015-10-30
IL238692A0 (en)	2015-06-30
TWI600663B (en)	2017-10-01
US9670261B2 (en)	2017-06-06
CL2016002182A1 (en)	2018-01-12
TWI602828B (en)	2017-10-21
KR20150096684A (en)	2015-08-25
AR094180A1 (en)	2015-07-15
US20140213513A1 (en)	2014-07-31
EA031428B1 (en)	2018-12-28
JP2016506401A (en)	2016-03-03
EP2934567B1 (en)	2018-05-09
SG10201705097PA (en)	2017-07-28
AR105816A2 (en)	2017-11-15
RU2652783C2 (en)	2018-05-03
MX362190B (en)	2019-01-08
KR20150099548A (en)	2015-08-31
HK1213483A1 (en)	2016-07-08
SG11201504215PA (en)	2015-06-29
MX360317B (en)	2018-10-29

Publication	Publication Date	Title
HRP20181300T1 (en)	2018-10-05	Exendin-4 derivatives as dual glp1/gip/glucagon agonists
ZA201501694B (en)	2016-01-27	Exendin-4 derivatives as dual glp1/glucagon agonists
HRP20190388T1 (en)	2019-04-19	Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists
HRP20181678T1 (en)	2019-03-08	Glucagon/glp-1 agonists for the treatment of obesity
HRP20181708T1 (en)	2018-12-28	Exendin-4 derivatives as selective glucagon receptor agonists
CO6980619A2 (en)	2014-06-27	Long-acting glucagon / glp-1 receptor agonists